CIK 0001849056
OKLO Oklo Inc.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at Oklo Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 53Moderate | sell 2 | Cochran Caroline Co-Founder, COO | $5.0M | 230,569 | -2% | - | |
| 58Moderate | sell 2 | DeWitte Jacob Co-Founder, CEO | $5.0M | 230,569 | -2% | - |
Transactions
The last 19 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | DeWitte Jacob Co-Founder, CEO | GGift Class A Common Stock | -35,000 | $0.00 | $0 | 13,068,926 | Dec 31, 2024 |
| Dec 30, 2024 | Cochran Caroline Co-Founder, COO | GGift Class A Common Stock | -35,000 | $0.00 | $0 | 12,508,085 | Dec 31, 2024 |
| Dec 30, 2024 | Cochran Caroline Co-Founder, COO | GGift Class A Common Stockindirect: By Jacob DeWitte | -35,000 | $0.00 | $0 | 13,068,926 | Dec 31, 2024 |
| Dec 30, 2024 | DeWitte Jacob Co-Founder, CEO | GGift Class A Common Stockindirect: By Caroline Cochran | -35,000 | $0.00 | $0 | 12,508,085 | Dec 31, 2024 |
| Dec 20, 2024 | Cochran Caroline Co-Founder, COO | SOpen-market sale Class A Common Stock | -2,321 | $20.24 | $47k | 12,771,333 | Dec 23, 2024 |
| Dec 20, 2024 | DeWitte Jacob Co-Founder, CEO | SOpen-market sale Class A Common Stockindirect: By Caroline Cochran | -2,321 | $20.24 | $47k | 12,771,333 | Dec 23, 2024 |
| Dec 20, 2024 | Cochran Caroline Co-Founder, COO | SOpen-market sale Class A Common Stock | -228,248 | $21.63 | $4.9M | 12,543,085 | Dec 23, 2024 |
| Dec 20, 2024 | DeWitte Jacob Co-Founder, CEO | SOpen-market sale Class A Common Stockindirect: By Caroline Cochran | -228,248 | $21.63 | $4.9M | 12,543,085 | Dec 23, 2024 |
| Nov 19, 2024 | Altman Samuel H. director | MOption exercise Class A Common Stockindirect: By Hydrazine Capital II, L.P. | +581,100 | - | - | 3,732,479 | Nov 21, 2024 |
| Nov 19, 2024 | Cochran Caroline Co-Founder, COO | MOption exercise Class A Common Stock | +1,862,054 | - | - | 12,773,654 | Nov 21, 2024 |
| Nov 19, 2024 | DeWitte Jacob Co-Founder, CEO | MOption exercise Class A Common Stock | +1,913,474 | - | - | 13,103,926 | Nov 21, 2024 |
| Nov 19, 2024 | Altman Samuel H. director | MOption exercise Earnout Rightsderivativeindirect: By Hydrazine Capital II, L.P. | -581,100 | - | - | 0 | Nov 21, 2024 |
| Nov 19, 2024 | DeWitte Jacob Co-Founder, CEO | MOption exercise Class A Common Stockindirect: By Caroline Cochran | +1,862,054 | - | - | 12,773,654 | Nov 21, 2024 |
| Nov 19, 2024 | Cochran Caroline Co-Founder, COO | MOption exercise Class A Common Stockindirect: By Jacob DeWitte | +1,913,474 | - | - | 13,103,926 | Nov 21, 2024 |
| Nov 19, 2024 | Cochran Caroline Co-Founder, COO | MOption exercise Earnout Rightsderivative | -1,862,054 | - | - | 0 | Nov 21, 2024 |
| Nov 19, 2024 | DeWitte Jacob Co-Founder, CEO | MOption exercise Earnout Rightsderivative | -1,913,474 | - | - | 0 | Nov 21, 2024 |
| Nov 19, 2024 | Cochran Caroline Co-Founder, COO | MOption exercise Earnout Rightsderivativeindirect: By Jacob DeWitte | -1,913,474 | - | - | 0 | Nov 21, 2024 |
| Nov 19, 2024 | DeWitte Jacob Co-Founder, CEO | MOption exercise Earnout Rightsderivativeindirect: By Caroline Cochran | -1,862,054 | - | - | 0 | Nov 21, 2024 |
| Nov 14, 2024 | Klein Michael Stuart director, owner | JOther Common Stock, par value $0.0001 per shareindirect: See footnote | -13,450,000 | $0.00 | $0 | 500,000 | Nov 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Altman Samuel H.director
- Cochran CarolineCo-Founder, COO
- DeWitte JacobCo-Founder, CEO
- Klein Michael Stuartdirector, owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.